Alpha Cognition (ACOG) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Alpha Cognition (ACOG) has outperformed Entrada Therapeutics (TRDA) over the past year, gaining 19.4% versus a loss of 16.5%. Entrada Therapeutics is the larger company by market cap ($220.8 million vs $196.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | TRDA |
|---|---|---|
| Share price | $9.04 | $5.67 |
| Market cap | $196.87M | $220.77M |
| 1-day change | 0.00% | +2.53% |
| YTD return | +39.08% | -44.84% |
| 1-year return | +19.42% | -16.49% |
| EPS (TTM) | $-1.32 | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.14 | $16.45 |
| 52-week low | $4.50 | $5.15 |
| Distance from 52-week high | -10.85% | -65.53% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +99.12% | +235.10% |
| Average volume | 125.72K | 355.24K |
| Shares outstanding | 21.78M | 38.94M |
| Employees | 71 | 152 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACOG has outperformed TRDA by 35.9 percentage points over the past year.
- The two companies sit in different sectors: Alpha Cognition in Healthcare and Entrada Therapeutics in Health Care.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
ACOG vs TRDA FAQ
Which is bigger, Alpha Cognition or Entrada Therapeutics?
Entrada Therapeutics (TRDA) is larger, with a market capitalization of $220.77M compared with $196.87M for Alpha Cognition (ACOG).
Which stock has performed better over the past year, ACOG or TRDA?
ACOG returned +19.42% over the past 12 months, compared with -16.49% for TRDA (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and Entrada Therapeutics in the same industry?
No. Alpha Cognition is in the Healthcare sector, while Entrada Therapeutics is in Health Care.